ORIGINAL PAPER
Skeletal complications in the course of neurofibromatosis in children
1
Department of Paediatric Propaedeutics and Bone Metabolism Diseases, Central Teaching Hospital of the Medical University of Lodz, Maria Konopnicka Paediatric Centre, Lodz, Poland
Submission date: 2019-03-05
Final revision date: 2019-04-17
Acceptance date: 2019-04-29
Publication date: 2019-06-28
Pediatr Pol 2019;94(3):151-157
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Type 1 neurofibromatosis (NF1) belongs to the group of phacomatoses characterised by the formation of neurofibromas in the course of the nerves. In some cases, it may also lead to lesser known skeletal symptoms such as disturbances in calcium-phosphate metabolism and decreased bone mineral density.
Aim of the study:
The purpose of this work is to analyse possible skeletal complications in the course of neurofibromatosis, based on presentation of patients with NF1.
Material and methods:
The study included 10 children diagnosed with NF1 (seven girls and three boys), aged four to 17 years. Medical examinations including evaluation of any motor system abnormalities, anthropometric measurements of body height and weight (to evaluate the respective parameters, centile charts were used from the OLAF project), and bone densitometry using dual-energy X-ray absorptiometry (DXA) were performed. Calcium and phosphate metabolisms were assessed based on laboratory tests (concentration of vitamin D – 25(OH)D, parathormone and alkaline phosphatase levels, and bone turnover markers).
Results:
Decreased body height was found in half of the patients (5/10). Typical dysplastic bone lesions were observed in 3/10 children. On densitometry, in nine out of 10 examined children a Z-score decrease to < –1.0 was observed, and in five children this value was ≤ –2.0. Decreased 25(OH)D concentration was found in 7/10 examined children. In three out of 10 patients the osteocalcin level was increased.
Conclusions:
NF1 may jeopardise normal development and function of the skeletal system in children – both of the mineral and bone metabolism. Assessment of the motor system and of the calcium and phosphate metabolism should be part of extended diagnosis and monitoring of this disease. Risk factors for bone fractures in children with NF1 are low bone mass and decreased vitamin D concentration.
Type 1 neurofibromatosis (NF1) belongs to the group of phacomatoses characterised by the formation of neurofibromas in the course of the nerves. In some cases, it may also lead to lesser known skeletal symptoms such as disturbances in calcium-phosphate metabolism and decreased bone mineral density.
Aim of the study:
The purpose of this work is to analyse possible skeletal complications in the course of neurofibromatosis, based on presentation of patients with NF1.
Material and methods:
The study included 10 children diagnosed with NF1 (seven girls and three boys), aged four to 17 years. Medical examinations including evaluation of any motor system abnormalities, anthropometric measurements of body height and weight (to evaluate the respective parameters, centile charts were used from the OLAF project), and bone densitometry using dual-energy X-ray absorptiometry (DXA) were performed. Calcium and phosphate metabolisms were assessed based on laboratory tests (concentration of vitamin D – 25(OH)D, parathormone and alkaline phosphatase levels, and bone turnover markers).
Results:
Decreased body height was found in half of the patients (5/10). Typical dysplastic bone lesions were observed in 3/10 children. On densitometry, in nine out of 10 examined children a Z-score decrease to < –1.0 was observed, and in five children this value was ≤ –2.0. Decreased 25(OH)D concentration was found in 7/10 examined children. In three out of 10 patients the osteocalcin level was increased.
Conclusions:
NF1 may jeopardise normal development and function of the skeletal system in children – both of the mineral and bone metabolism. Assessment of the motor system and of the calcium and phosphate metabolism should be part of extended diagnosis and monitoring of this disease. Risk factors for bone fractures in children with NF1 are low bone mass and decreased vitamin D concentration.
REFERENCES (27)
1.
Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revised. Pediatrics 2009; 123: 124-133.
2.
Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-186.
3.
Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111: 1355-1381.
4.
Reynolds RM, Browning GG, Nawroz I, Campbell IW. Von Recklinghausen’s neurofibromatosis: neurofibromatosis type 1. Lancet 2003; 361: 1552-1554.
5.
National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis 1988, 1: 172-178.
6.
Alwan S, Armstrong L, Joe H, et al. Associations of osseous abnormalities in Neurofibromatosis 1. Am J Med Genet A 2007; 143A: 1326-1333.
7.
Stevenson DA, Carey JC, Viskochil DH, et.al. Analysis of radiographic characteristics of anterolateral bowing of the leg before fracture in neurofibromatosis type 1. J Pediatr Orthop 2009; 29: 385-392.
8.
Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized Metabolic Bone Disease in Neurofibromatosis Type I. Mol Genet Metab 2008; 94: 105-111.
9.
Lammert M, Kappler M, Mautner VF, et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 2005; 16: 1161-1166.
10.
Stevenson DA, Viskochil DH, Carey JC, et al. Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1. J Pediatr Endocrinol Metab 2011; 24: 169-174.
11.
Dulai S, Briody J, Schindeler A, et al. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort.
13.
Gajewska J, Ambroszkiewicz J, Laskowska-Klita T. Biochemical markers of bone turnover and their use. Med Wieku Rozwoj 1999; 3: 421-432.
14.
Friedman JM. Neurofibromatosis 1: Clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17: 548-554, discussion 571-572, 646-651.
15.
Janus D, Wojcik M, Kalicka-Kasperczyk A, et al. Neurofibromatosis type I-the pediatric endocrinologist’s point of view. Przegl Lek 2010; 67: 1155-1159.
16.
Greggi T, Martikos K. Surgical treatment of early onset scoliosis in neurofibromatosis. Stud Health Technol Inform 2012; 176: 330-333.
17.
Crawford AH, Herrera-Soto J. Scoliosis associated with neurofibromatosis. Orthop Clin North Am 2007; 38: 553-562, vii.
18.
Stevenson DA, Zhou H, Ashrafi S, et al. Double inactivation of NF1 in tibia pseudarthrosis. Am J Hum Genet 2006; 79: 143-148.
19.
Birke O, Schindeler A, Ramachandran M, et al. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 2010; 4: 507-517.
20.
Trigui M, Ayadi K, Sakka M, et al. Orthopaedic manifestations of Von Recklinghausen’s neurofibromatosis. Presse Med 2011; 40: e152-162.
21.
Alwan S, Tredwell SJ, Friedman JM. Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet 2005; 67: 378-390.
22.
Stevenson DA, Moyer-Mileur LJ, Murray M, et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 2007; 150: 83-88.
23.
Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr 2007; 96: 1220-1222.
24.
Lammert M, Friedman JM, Roth HJ, et al. Vitamin D deficiency associated with number of neurofibroma in neurofibromatosis 1.
26.
Schnabel C, Jett K, Friedman JM, et al. Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Joint Bone Spine 2013; 80: 315-319.
27.
Petramala L, Giustini S, Zinnamosca L, et al. Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 2012; 304: 325-331.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
